Bio­Marin CEO JJ Bi­en­aimé is plan­ning for a block­buster fu­ture in the gene ther­a­py biz: to the tune of $10B to $15B a year

The eco­nom­ics of gene ther­a­py has cap­tured just about every­one’s at­ten­tion in the in­dus­try. This first wave is faced with stub­born ques­tions about dura­bil­i­ty, the race to first-in-class sta­tus as well as the sticky is­sue of just how much mon­ey you can make from these sup­pos­ed­ly once-and-done ther­a­pies that can cure pa­tients of some ter­ri­ble dis­eases.

Bio­Marin CEO Jean-Jacques Bi­en­aimé felt the full force of that blow­back from a range of an­a­lysts in yes­ter­day’s Q4 call. And at one point in the con­ver­sa­tion, he of­fered a snap­shot of what the fu­ture could look like — and it’s a big one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER